Farther Finance Advisors LLC Acquires 878 Shares of Sanofi (NASDAQ:SNY)

Farther Finance Advisors LLC boosted its holdings in shares of Sanofi (NASDAQ:SNY) by 30.7% during the 4th quarter, according to the company in its most recent disclosure with the SEC. The institutional investor owned 3,739 shares of the company’s stock after acquiring an additional 878 shares during the quarter. Farther Finance Advisors LLC’s holdings in Sanofi were worth $180,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors have also recently added to or reduced their stakes in the business. Sequoia Financial Advisors LLC raised its position in Sanofi by 2.1% during the fourth quarter. Sequoia Financial Advisors LLC now owns 21,003 shares of the company’s stock valued at $1,013,000 after acquiring an additional 425 shares in the last quarter. HighTower Advisors LLC raised its position in Sanofi by 3.4% during the fourth quarter. HighTower Advisors LLC now owns 91,071 shares of the company’s stock valued at $4,392,000 after acquiring an additional 2,971 shares in the last quarter. Wealthfront Advisers LLC bought a new position in Sanofi during the fourth quarter valued at approximately $1,908,000. Meriwether Wealth & Planning LLC bought a new position in Sanofi during the fourth quarter valued at approximately $587,000. Finally, Amundi raised its position in shares of Sanofi by 11.1% in the fourth quarter. Amundi now owns 630,063 shares of the company’s stock valued at $31,017,000 after purchasing an additional 63,195 shares during the period. Institutional investors own 14.04% of the company’s stock.

Analysts Set New Price Targets

A number of equities analysts have recently commented on the stock. Sanford C. Bernstein raised shares of Sanofi to a “strong-buy” rating in a research report on Thursday, January 30th. StockNews.com lowered shares of Sanofi from a “buy” rating to a “hold” rating in a research report on Thursday, December 12th. Finally, Deutsche Bank Aktiengesellschaft raised shares of Sanofi from a “sell” rating to a “hold” rating in a research report on Thursday, January 30th. Two analysts have rated the stock with a hold rating, one has assigned a buy rating and two have assigned a strong buy rating to the stock. According to data from MarketBeat, Sanofi currently has an average rating of “Buy” and a consensus target price of $60.00.

Sanofi Trading Down 0.9 %

Shares of Sanofi stock opened at $58.60 on Thursday. The company’s fifty day simple moving average is $54.22 and its 200-day simple moving average is $52.89. The company has a market cap of $148.72 billion, a price-to-earnings ratio of 23.53, a PEG ratio of 1.01 and a beta of 0.58. The company has a current ratio of 1.46, a quick ratio of 1.14 and a debt-to-equity ratio of 0.15. Sanofi has a 1 year low of $45.22 and a 1 year high of $60.12.

Sanofi (NASDAQ:SNY) last announced its quarterly earnings data on Thursday, January 30th. The company reported $0.70 earnings per share (EPS) for the quarter, hitting the consensus estimate of $0.70. Sanofi had a net margin of 12.77% and a return on equity of 25.61%. As a group, sell-side analysts expect that Sanofi will post 4.36 EPS for the current year.

Sanofi Company Profile

Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, Canada, and internationally. It operates through Pharmaceuticals, Vaccines, and Consumer Healthcare segments. The company provides specialty care, such as DUPIXENT, neurology and immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes and cardiovascular diseases; and established prescription products.